TKT Replagal Renal Function Trial To Be Submitted By Year-End
Executive Summary
Transkaryotic Therapies will submit data from a Phase III trial evaluating renal function in Fabry disease patients treated with Replagal by the end of the year, CEO Richard Selden, MD/PhD, said Oct. 30
You may also be interested in...
CBER’s Long Goodbye: Biologics Approval Time Jumps To 30 Months In 2002
The average approval time for new biologic therapeutics and vaccines in 2002 was 30.1 months, an 11-month increase from 2001
CBER’s Long Goodbye: Biologics Approval Time Jumps To 30 Months In 2002
The average approval time for new biologic therapeutics and vaccines in 2002 was 30.1 months, an 11-month increase from 2001
Replagal Advisory Committee Meeting Possible By End Of The Year, TKT Says
FDA's Endocrinologic & Metabolic Drugs Advisory Committee may consider Transkaryotic Therapies' Fabry Disease treatment, Replagal (agalsidase alfa), before the end of the year, TKT said